Abstract
A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.
| Original language | English |
|---|---|
| Pages (from-to) | 556 |
| Number of pages | 1 |
| Journal | Pharmatherapeutica |
| Volume | 3 |
| Issue number | 8 |
| Publication status | Published - 1984 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections. / Colombo, M. L.; Peona, V.; Ginesu, F.; Ortu, A. R.; Bagnato, A.; Dei, D.; Colombo, F.; Donno, L.
In: Pharmatherapeutica, Vol. 3, No. 8, 1984, p. 556.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A multi-centre trial comparing a sulfamethopyrazine/trimethoprim combination with co-trimoxazole in respiratory tract infections
AU - Colombo, M. L.
AU - Peona, V.
AU - Ginesu, F.
AU - Ortu, A. R.
AU - Bagnato, A.
AU - Dei, D.
AU - Colombo, F.
AU - Donno, L.
PY - 1984
Y1 - 1984
N2 - A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.
AB - A double-blind, multi-centre trial was carried out in 72 patients with acute or chronic infections of the lower respiratory tract to compare the efficacy and tolerance of a sulfamethopyrazine (200 mg)/trimethoprim (250 mg) combination with that of the established combination cotrimoxazole (400 mg sulphamethoxazole plus 80 mg trimethoprim). Patients received treatment for 10 days either with 2 capsules of co-trimoxazole twice daily or in the newer combination group, with 2 capsules on Day 1 and then 1 capsule daily for the remainder of the treatment period. The results of clinical, bacteriological and functional tests showed an excellent or good response in over 90% of patients in each group. There was no statistically significant difference in effectiveness of treatment with the once-daily sulfamethopyrazine/trimethoprim regimen compared with co-trimoxazole given twice daily. Both treatments were well tolerated, with only a few mild side-effects, mainly gastro-intestinal ones, being reported.
UR - http://www.scopus.com/inward/record.url?scp=0021350783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021350783&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 556
JO - Pharmatherapeutica
JF - Pharmatherapeutica
SN - 0308-051X
IS - 8
ER -